Title
Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy
Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
30mg/20mL vial, twice per day, not longer than two weeks
Inclusion Criteria: Acute ischemic stroke < 24 hours of onset Measurable neurological deficits caused by the present attack, ranging from 1 to 22 of NIHSS score on admission Exclusion Criteria: Definite or possible cardiogenic brain infarction Definite lacunar infarction Prior ischemic stroke within 6 months Evidence of hemorrhagic brain infarction, epidural hematoma, intracerebral hematoma, or intraventricular hemorrhage Severe consciousness disturbances (semicoma to deep coma) Neurological signs clearing spontaneously Disability of 2 or more on mRS score before the index stroke aPTT being out of the normal range or 1.5 times longer than the pretreatment value If taking an oral anticoagulant, INR being 1.6 or more, or no INR data Treatment with urokinase, t-PA, heparin, ozagrel sodium, warfarin, or antiplatelet except for aspirin before enrollment Intravascular surgery, surgical operation, hyperbaric oxygen therapy, or hypothermia therapy before enrollment Serum creatinine >1.5 mg/dL Severe hepatic or cardiac disorders, infectious disorders, dehydration, etc. Neoplasm Pregnancy Hypersensitivity to test drugs
